Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 2 min 49 sec ago

Ultragenyx Appoints Daniel G. Welch to Board of Directors

Mon, 04/13/2015 - 15:33
NOVATO, Calif., April 13, 2015 -- (Healthcare Sales & Marketing Network) -- Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the appointment of...
Biopharmaceuticals, Personnel
Ultragenyx Pharmaceutical

Takeda Announces Appointment of New President of U.S. Business Unit

Mon, 04/13/2015 - 15:31
DEERFIELD, Ill., April 13, 2015 -- (Healthcare Sales & Marketing Network) -- Takeda Pharmaceutical Company Limited ("Takeda"), and Takeda's wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA") announced today that Ram...
Biopharmaceuticals, Personnel
Takeda Pharmaceutical

Depomed Announces Gralise(R) ANDA Litigation Settlement Confirming Exclusivity to 2024 and Dismissing Appeal

Mon, 04/13/2015 - 15:27
NEWARK, Calif., April 13, 2015 -- (Healthcare Sales & Marketing Network) -- Depomed, Inc. (DEPO) today announced it has entered into a settlement agreement with Actavis, Inc. in Depomed's patent infringement litigation related to Actavis's Abbreviated New...
Biopharmaceuticals, Generics, Litigation
Depomed, Actavis, Gralise, gabapentin

Radius Health Today Announced That it Has Appointed Brent Hatzis-Schoch as Senior Vice President and General Counsel

Fri, 04/10/2015 - 14:18
WALTHAM, Mass., April 10, 2015 -- (Healthcare Sales & Marketing Network) -- Radius Health, Inc. (RDUS) a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediate...
Biopharmaceuticals, Personnel
Radius Health

Horizon Pharma plc Receives FDA Fast Track Designation for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia

Fri, 04/10/2015 - 13:22
DUBLIN, IRELAND--(Healthcare Sales & Marketing Network) - Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that a...
Biopharmaceuticals, Neurology, FDA
Horizon Pharma, ACTIMMUNE, Friedreich's Ataxia

Caris Life Sciences Appoints Dr. David Spetzler Chief Scientific Officer

Thu, 04/09/2015 - 12:23
Executive Appointment Complements Strategic Alignment to Further Develop and Expand Carisome TOP Platform IRVING, Texas, April 9, 2015 -- (Healthcare Sales & Marketing Network) -- Caris Life Sciences®, a leading biotechnology company focused on ful...
Biopharmaceuticals, Personnel
Caris Life Sciences, Carisome TOP

PTC Therapeutics Names Eric Pauwels SVP and General Manager Commercial Operations, Americas

Wed, 04/08/2015 - 15:30
SOUTH PLAINFIELD, N.J., April 8, 2015 -- (Healthcare Sales & Marketing Network) -- PTC Therapeutics, Inc. (PTCT), today announced the appointment of Eric Pauwels as Senior Vice President and General Manager Commercial Operations, Americas. Eric will be re...
Biopharmaceuticals, Personnel
PTC Therapeutics, Translarna

Alzheon Announces $10 Million Series A Financing

Wed, 04/08/2015 - 13:48
Funding to Advance ALZ-801 Toward a Pivotal Clinical Study in Alzheimer’s Disease FRAMINGHAM, Mass.--(Healthcare Sales & Marketing Network)--Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced t...
Biopharmaceuticals, Neurology
Alzheon, Alzheimer’s disease

ArmaGen Announces FDA Acceptance of IND Application for AGT-181 for the Treatment of Hurler Syndrome

Wed, 04/08/2015 - 13:39
CALABASAS, Calif., April 8, 2015 -- (Healthcare Sales & Marketing Network) -- ArmaGen, Inc., a privately held biotechnology company focused on developing novel therapies to treat severe neurological disorders, announced today that the Investigational New ...
Biopharmaceuticals, Neurology
ArmaGen, AGT-181, Hurler syndrome

True North Therapeutics Announces $35 Million Series B Financing

Tue, 04/07/2015 - 13:37
Company to advance multiple product pipeline of novel monoclonal antibodies for rare diseases targeting the Complement system Lead Complement inhibitor, TNT009, to enter clinical development SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing...
Biopharmaceuticals, Venture Capital
True North Therapeutics

FDA Expands Indication for EVARREST(R) Fibrin Sealant Patch

Mon, 04/06/2015 - 15:57
Surgeons Have New Solution for Controlling Problematic Bleeding Situations During Adult Liver Surgery SOMERVILLE, N.J., April 6, 2015 -- (Healthcare Sales & Marketing Network) -- Unexpected and uncontrollable bleeding is an ongoing challenge for surgeo...
Devices, Surgery, FDA
Ethicon, EVARREST, Fibrin Sealant

Natera, Inc., Non-Invasive Genetic Testing Leader, Secures $55 Million in Private Financing

Mon, 04/06/2015 - 15:40
Funding to Expand Global Sales and Marketing, and Support Research and Development for Existing Products and Cancer Monitoring SAN CARLOS, Calif., April 6, 2015 -- (Healthcare Sales & Marketing Network) -- Natera, Inc., a leader in non-invasive genetic...
Diagnostics, Venture Capital

VytronUS, Inc. Attracts Industry Veteran John Pavlidis as New President and Chief Executive Officer

Mon, 04/06/2015 - 15:34
Bolsters high-quality management team with more than twenty-five years of highly relevant medical device experience and enhances highly accomplished Board of Directors SUNNYVALE, Calif., April 6, 2015 -- (Healthcare Sales & Marketing Network) -- Vytron...
Devices, Cardiology, Personnel
VytronUS, Low-Intensity Collimated Ultrasound, LICU

European Commission Approves Amgen's Vectibix(R) (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Metastatic Colorectal Cancer

Mon, 04/06/2015 - 13:45
Important Step Towards Increasing Treatment Options for Patients With This Serious Disease THOUSAND OAKS, Calif., April 6, 2015 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) today announced that the European Commission approved a new use of...
Biopharmaceuticals, Oncology, Regulatory
Amgen, Vectibix, panitumumab, metastatic colorectal cancer

MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia

Fri, 04/03/2015 - 16:12
TOKYO and HOUSTON, April 3, 2015 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE:4503) and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and develop a new treatment ...
Biopharmaceuticals, Oncology, Licensing
Astellas Pharma, MD Anderson, acute myeloid leukemia

Bruker Announces FDA Clearance for Second, Expanded Claim for the MALDI Biotyper CA System

Fri, 04/03/2015 - 16:07
BILLERICA, Mass.--(Healthcare Sales & Marketing Network)--Bruker (BRKR) today announced that it has received 510(k) clearance from the US Food and Drug Administration for library and methods expansion for the MALDI Biotyper CA System, sold in the United St...
Diagnostics, FDA
Bruker Corp, MALDI BioTyper

Augmenix Announces FDA Clearance of SpaceOAR(R) System

Thu, 04/02/2015 - 15:43
WALTHAM, Mass.--(Healthcare Sales & Marketing Network)--Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, today announced FDA clearance of the SpaceOAR® System, t...
Devices, Oncology, FDA
Augmenix, SpaceOAR, prostate cancer, radiotherapy

Ethicon’s HARMONIC FOCUS(R)+ Shears Now Proven to Produce Vessel Seal Strength Equivalent to Advanced Bipolar Devices

Thu, 04/02/2015 - 15:35
Ultrasonic device known for meticulous dissection now produces lower tissue temperature and less thermal damage critical when working near nerves CINCINNATI--(Healthcare Sales & Marketing Network)--Ethicon*, a leading global provider of medical devices,...
Devices, Surgery
Ethicon, HARMONIC FOCUS, hemostasis

Perosphere Receives FDA Fast Track Designation for Investigational Anticoagulant Reversal Agent PER977

Thu, 04/02/2015 - 15:24
DANBURY, Conn.--(Healthcare Sales & Marketing Network)--Perosphere Inc. today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for PER977, an investigational anticoagulant reversal agent. The FDA established the ...
Biopharmaceuticals, FDA
Perosphere, PER977, anticoagulant, anticoagulant reversal

Boston Scientific Agrees to Acquire Xlumena

Wed, 04/01/2015 - 20:54
MARLBOROUGH, Mass. and MOUNTAIN VIEW, Calif., April 1, 2015 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (BSX) announces that it has signed a definitive agreement to acquire Xlumena, Inc., a venture-backed medical device comp...
Devices, Interventional, Mergers & Acquisitions
Boston Scientific, Xlumena, Endoscopic Ultrasound, pancreatic pseudocyst

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong